WO2003006444A3 - Amides substitues, sulfonamides et urees utiles pour inhiber l'activite de la kinase - Google Patents

Amides substitues, sulfonamides et urees utiles pour inhiber l'activite de la kinase Download PDF

Info

Publication number
WO2003006444A3
WO2003006444A3 PCT/US2002/021525 US0221525W WO03006444A3 WO 2003006444 A3 WO2003006444 A3 WO 2003006444A3 US 0221525 W US0221525 W US 0221525W WO 03006444 A3 WO03006444 A3 WO 03006444A3
Authority
WO
WIPO (PCT)
Prior art keywords
sulfonamides
kinase activity
substituted amides
inhibiting kinase
ureas useful
Prior art date
Application number
PCT/US2002/021525
Other languages
English (en)
Other versions
WO2003006444A2 (fr
Inventor
Pavel Safar
Armin Walser
Stephen J Shimshock
Original Assignee
Aventis Pharma Inc
Pavel Safar
Armin Walser
Stephen J Shimshock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0127615.3A external-priority patent/GB0127615D0/en
Priority to AU2002320330A priority Critical patent/AU2002320330B2/en
Priority to IL15973502A priority patent/IL159735A0/xx
Priority to DE60206782T priority patent/DE60206782T2/de
Priority to EP02749842A priority patent/EP1423373B1/fr
Priority to CA002453169A priority patent/CA2453169A1/fr
Application filed by Aventis Pharma Inc, Pavel Safar, Armin Walser, Stephen J Shimshock filed Critical Aventis Pharma Inc
Priority to MXPA04000040A priority patent/MXPA04000040A/es
Priority to JP2003512216A priority patent/JP4320249B2/ja
Priority to AT02749842T priority patent/ATE307125T1/de
Publication of WO2003006444A2 publication Critical patent/WO2003006444A2/fr
Priority to IL159735A priority patent/IL159735A/en
Publication of WO2003006444A3 publication Critical patent/WO2003006444A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des composés d'amide, de sulfonamide et d'urée présentant un effet inhibiteur sur la kinase Src, notamment des énantionmères, stéréoisomères, tautomères de ceux-ci, ainsi que des sels ou solvates pharmaceutiquement acceptables de ces composés, lesquels possèdent la structure générale représentée par les formules (I) et (II).
PCT/US2002/021525 2001-07-09 2002-07-09 Amides substitues, sulfonamides et urees utiles pour inhiber l'activite de la kinase WO2003006444A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AT02749842T ATE307125T1 (de) 2001-07-09 2002-07-09 Substituierte amide, sulfonamide und harnstoffe mit kinasehemmender wirkung
IL15973502A IL159735A0 (en) 2001-07-09 2002-07-09 Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity
DE60206782T DE60206782T2 (de) 2001-07-09 2002-07-09 Substituierte amide, sulfonamide und harnstoffe mit kinasehemmender wirkung
EP02749842A EP1423373B1 (fr) 2001-07-09 2002-07-09 Amides substitues, sulfonamides et urees utiles pour inhiber l'activite de la kinase
CA002453169A CA2453169A1 (fr) 2001-07-09 2002-07-09 Amides substitues, sulfonamides et urees utiles pour inhiber l'activite de la kinase
AU2002320330A AU2002320330B2 (en) 2001-07-09 2002-07-09 Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity
MXPA04000040A MXPA04000040A (es) 2001-07-09 2002-07-09 Amidas sustituidas, sulfonamida y ureas utiles para la inhibicion de la actividad de quinasas.
JP2003512216A JP4320249B2 (ja) 2001-07-09 2002-07-09 キナーゼ活性を阻害するのに有用な置換アミド、スルホンアミド及び尿素
IL159735A IL159735A (en) 2001-07-09 2004-01-06 Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30402001P 2001-07-09 2001-07-09
US60/304,020 2001-07-09
GBGB0127615.3A GB0127615D0 (en) 2001-07-09 2001-11-19 Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity
GB0127615.3 2001-11-19

Publications (2)

Publication Number Publication Date
WO2003006444A2 WO2003006444A2 (fr) 2003-01-23
WO2003006444A3 true WO2003006444A3 (fr) 2004-03-11

Family

ID=26246780

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/021525 WO2003006444A2 (fr) 2001-07-09 2002-07-09 Amides substitues, sulfonamides et urees utiles pour inhiber l'activite de la kinase

Country Status (9)

Country Link
EP (1) EP1423373B1 (fr)
AT (1) ATE307125T1 (fr)
AU (1) AU2002320330B2 (fr)
CA (1) CA2453169A1 (fr)
DE (1) DE60206782T2 (fr)
ES (1) ES2247357T3 (fr)
IL (1) IL159735A0 (fr)
MX (1) MXPA04000040A (fr)
WO (1) WO2003006444A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130209A1 (en) * 1999-12-22 2003-07-10 Cheresh David A. Method of treatment of myocardial infarction
US7427683B2 (en) * 2003-04-25 2008-09-23 Ortho-Mcneil Pharmaceutical, Inc. c-fms kinase inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000049018A1 (fr) * 1999-02-18 2000-08-24 Novartis Ag 2-amino-6-anilino-purines et leur utilisation comme medicaments

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000049018A1 (fr) * 1999-02-18 2000-08-24 Novartis Ag 2-amino-6-anilino-purines et leur utilisation comme medicaments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PECK W.A. ET AL.: "CONSENSUS DEVELOPMENT CONFERENCE: DIAGNOSIS, PROPHYLAXIS, AND TREATMENT OF OSTEOPOROSIS", AMERICAN JOURNAL OF MEDICINE, vol. 94, no. 6, 1993, pages 646 - 650, XP008017481 *

Also Published As

Publication number Publication date
ES2247357T3 (es) 2006-03-01
CA2453169A1 (fr) 2003-01-23
AU2002320330B2 (en) 2007-06-14
MXPA04000040A (es) 2004-05-21
IL159735A0 (en) 2004-06-20
EP1423373B1 (fr) 2005-10-19
ATE307125T1 (de) 2005-11-15
WO2003006444A2 (fr) 2003-01-23
EP1423373A2 (fr) 2004-06-02
DE60206782D1 (de) 2006-03-02
DE60206782T2 (de) 2006-07-13

Similar Documents

Publication Publication Date Title
WO2003050087A3 (fr) Herbicides nouveaux
WO2004002981A3 (fr) Nouveaux herbicides
WO2003048081A3 (fr) Glycinamides en tant qu'inhibiteurs du facteur xa
WO2004037176A3 (fr) Quinazolinones et derives de celles-ci comme inhibiteurs du facteur xa
MXPA04001685A (es) Derivados de sulfonilamino empleados como herbicida.
GB0124933D0 (en) Chemical compounds
WO2004031401A3 (fr) Nouveaux inhibiteurs de tyrosine kinases
RS92004A (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
WO2003047520A3 (fr) Inhibiteurs de facteur xa a aminomethyle substitue
AU2001230564A1 (en) Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
JO2311B1 (en) Alkyl inhibitors Ariel phosphodiesterase-4
WO2004043367A3 (fr) Composes heterocycliques fusionnes et leur utilisation
EP1864665A4 (fr) Agent immunosuppressif et agent anti-tumoral comprenant un compose heterocyclique en tant que principe actif
EP1889842A4 (fr) Composé hétérocyclique
WO2004018465A3 (fr) Nouvelles benzonaphtyridines
WO2005020899A3 (fr) Derives de cycloalkyamine substitues en tant que modulateurs de l'activite du recepteur de la chimiokine
WO2000059902A3 (fr) Sulfonyles aryles faisant office d'inhibiteurs du facteur xa
WO2003037860A3 (fr) Analogues de purine presentant une activite inhibitrice de hsp90
WO2003047512A3 (fr) Composes derives d'un noyau d'amine nucleus et compositions pharmaceutiques renfermant ceux-ci
WO2004063151A3 (fr) Nouveaux inhibiteurs de tyrosine kinase
WO2002085906A3 (fr) Phtalazinones
WO2001032652A3 (fr) Dérivés carbamoyloxyalkyl-azolium n-substitués
MXPA03009750A (es) Compuestos quimicos.
WO2004014868A3 (fr) Derives de pyrimidine 2,4-diones, utilises comme inhibiteurs de metalloproteinase matricielle
WO2003053971A8 (fr) Antiviraux a base de pyridoquinoxaline

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG US

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002320330

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002749842

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 159735

Country of ref document: IL

Ref document number: 2453169

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/A/2004/000040

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003512216

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002749842

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002749842

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002320330

Country of ref document: AU